Unknown

Dataset Information

0

AP-2α gene deregulation is associated with renal cell carcinoma patient survival.


ABSTRACT:

Background

Renal cell carcinoma (RCC), one of the most fatal urologic tumors, accounts for approximately 3% of all adult cancers and exhibits a high metastatic index at diagnosis and a high rate of relapse. Radical or partial nephrectomy is a curative option for nonmetastatic RCCs. Targeted therapy has been shown to improve the survival of patients with metastatic RCCs. However, the underlying cellular and molecular events associated with RCC pathogenesis are not well known.

Methods

To investigate the clinical role of the transcription factor activator protein (AP)-2α in RCC, methylated CpG island recovery assays and microarray analysis were employed. COBRA and RT‒qPCR assays were performed to assess AP-2α expression in RCC.

Results

A negative correlation was noted between AP-2α mRNA expression levels and methylation status. Multivariate analyses showed that AP-2α mRNA was a major risk factor not only for overall and disease-free survival in RCC but also for disease-free survival in clear cell RCC.

Conclusions

Our results indicated that AP-2α expression was deregulated in RCC and associated with overall patient survival and disease-free survival. Such findings suggest that AP-2α might play an important role in the pathogenesis of RCC.

SUBMITTER: Lin PH 

PROVIDER: S-EPMC11304775 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

AP-2α gene deregulation is associated with renal cell carcinoma patient survival.

Lin Po-Hung PH   Hsieh Chin-Hsuan CH   Yu Kai-Jie KJ   Shao I-Hung IH   Chuang Cheng-Keng CK   Hsu Todd T   Weng Wen-Hui WH   Pang See-Tong ST  

BMC cancer 20240807 1


<h4>Background</h4>Renal cell carcinoma (RCC), one of the most fatal urologic tumors, accounts for approximately 3% of all adult cancers and exhibits a high metastatic index at diagnosis and a high rate of relapse. Radical or partial nephrectomy is a curative option for nonmetastatic RCCs. Targeted therapy has been shown to improve the survival of patients with metastatic RCCs. However, the underlying cellular and molecular events associated with RCC pathogenesis are not well known.<h4>Methods</  ...[more]

Similar Datasets

| S-EPMC3587206 | biostudies-literature
| S-EPMC11832949 | biostudies-literature
| S-EPMC5825845 | biostudies-literature
| S-EPMC3281492 | biostudies-literature
| S-EPMC1298943 | biostudies-literature
| S-EPMC6902018 | biostudies-literature
| S-EPMC8033537 | biostudies-literature
| S-EPMC10854987 | biostudies-literature
| S-EPMC7666730 | biostudies-literature
| S-EPMC5347726 | biostudies-literature